These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 7937354)

  • 21. On the significance of cholecystokinin receptors in panic disorder.
    van Megen HJ; den Boer JA; Westenberg HG
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 Dec; 18(8):1235-46. PubMed ID: 7863014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion.
    Hebb AL; Poulin JF; Roach SP; Zacharko RM; Drolet G
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Dec; 29(8):1225-38. PubMed ID: 16242828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholecystokinin-dopamine interactions.
    Crawley JN
    Trends Pharmacol Sci; 1991 Jun; 12(6):232-6. PubMed ID: 2048219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological activity of cholecystokinin analogues modified in the Met28-Gly29 region.
    Mendre C; Rodriguez M; Lignon MF; Galas MC; Gueudet C; Worms P; Martinez J
    Eur J Pharmacol; 1990 Sep; 186(2-3):213-22. PubMed ID: 1705230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropeptides and anxiety: focus on cholecystokinin.
    Lydiard RB
    Clin Chem; 1994 Feb; 40(2):315-8. PubMed ID: 8313613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cholecystokinin and cholecystokinin receptor].
    Funakoshi A
    Nihon Rinsho; 1996 Apr; 54(4):1097-1103. PubMed ID: 8920681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
    Durieux C; Ruiz-Gayo M; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Release of cholecystokinin in the central nervous system.
    Raiteri M; Paudice P; Vallebuona F
    Neurochem Int; 1993 Jun; 22(6):519-27. PubMed ID: 8513278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum.
    Loonam TM; Noailles PA; Yu J; Zhu JP; Angulo JA
    Life Sci; 2003 Jun; 73(6):727-39. PubMed ID: 12801594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of CCK in gallbladder function.
    Schjoldager BT
    Ann N Y Acad Sci; 1994 Mar; 713():207-18. PubMed ID: 8185161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single amino acid substitution of serine82 to asparagine in first intracellular loop of human cholecystokinin (CCK)-B receptor confers full cyclic AMP responses to CCK and gastrin.
    Wu SV; Yang M; Avedian D; Birnbaumer M; Walsh JH
    Mol Pharmacol; 1999 May; 55(5):795-803. PubMed ID: 10220557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major biological actions of CCK--a critical evaluation of research findings.
    Fink H; Rex A; Voits M; Voigt JP
    Exp Brain Res; 1998 Nov; 123(1-2):77-83. PubMed ID: 9835394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of dorsolateral periaqueductal gray cholecystokinin-2 receptors in the regulation of a panic-related behavior in rats.
    Bertoglio LJ; Zangrossi H
    Brain Res; 2005 Oct; 1059(1):46-51. PubMed ID: 16168394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCK-B/Gastrin receptor transmembrane domain mutations selectively alter synthetic agonist efficacy without affecting the activity of endogenous peptides.
    Bläker M; Ren Y; Seshadri L; McBride EW; Beinborn M; Kopin AS
    Mol Pharmacol; 2000 Aug; 58(2):399-406. PubMed ID: 10908308
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for an endogenous cholecystokininergic balance in social memory.
    Lemaire M; Piot O; Roques BP; Böhme GA; Blanchard JC
    Neuroreport; 1992 Oct; 3(10):929-32. PubMed ID: 1421101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ghrelin, neuropeptide Y (NPY) and cholecystokinin (CCK) in blunt snout bream (Megalobrama amblycephala): cDNA cloning, tissue distribution and mRNA expression changes responding to fasting and refeeding.
    Ji W; Ping HC; Wei KJ; Zhang GR; Shi ZC; Yang RB; Zou GW; Wang WM
    Gen Comp Endocrinol; 2015 Nov; 223():108-19. PubMed ID: 26316038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.
    Rotzinger S; Vaccarino FJ
    J Psychiatry Neurosci; 2003 May; 28(3):171-81. PubMed ID: 12790157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.